Janssen Announces SVR12 Rates with Twelve Weeks of Treatment with All-Oral, Once-Daily Regimen of Simeprevir Plus Sofosbuvir in Genotype 1 HCV Patients With and Without Cirrhosis

Press/Media: Press / Media

PeriodApr 23 2015 → Apr 24 2015

Media coverage

2

Media coverage

  • TitleJanssen Announces SVR12 Rates with Twelve Weeks of Treatment with All-Oral, Once-Daily Regimen of Simeprevir Plus Sofosbuvir in Genotype 1 HCV Patients With and Without Cirrhosis
    Media name/outletNational AIDS Treatment Advocacy Project
    CountryUnited States
    Date4/24/15
    PersonsEric J Lawitz
  • TitleJanssen Announces SVR12 Rates with Twelve Weeks of Treatment with All-Oral, Once-Daily Regimen of Simeprevir Plus Sofosbuvir in Genotype 1 HCV Patients With and Without Cirrhosis
    Media name/outletPharmacy Choice
    CountryUnited States
    Date4/23/15
    PersonsEric J Lawitz